Enliven Therapeutics, Inc. (ELVN) Stock Price & Analysis
Enliven Therapeutics, Inc. (ELVN) rose 7.37% to USD 36.11 as of June 10, 2026 at 01:10 UTC, according to Nexqual real-time market data.
ELVN last closed at USD 33.63; the session ranged USD 34.21–36.21 on volume of 1,833,070 shares. Market capitalization is $2.20B, with a 52-week range of USD 14.79–48.53 (NMS). Source: Nexqual, June 10, 2026 at 01:10 UTC.
Key Statistics (as of June 10, 2026 at 01:10 UTC)
| Price | USD 36.11 |
|---|---|
| Change | ▲ 7.37% (up) |
| Previous Close | USD 33.63 |
| Open | USD 34.4 |
| Day Range | USD 34.21 – 36.21 |
| 52-Week Range | USD 14.79 – 48.53 |
| Volume | 1,833,070 shares |
| Market Cap | $2.20B |
| Exchange | NMS |
Technical Analysis (ELVN)
Nexqual's technical model rates ELVN "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:10 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.54 (neutral) |
| vs SMA50 | Below (USD 41.33) |
| MACD | -1.67 (negative) |
Analyst Ratings (ELVN)
Wall Street analysts rate ELVN "Strong Buy" based on 9 analysts, with a mean price target of USD 59.22 (range USD 45–80), per Nexqual as of June 10, 2026 at 01:10 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 59.22 |
| High Target | USD 80 |
| Low Target | USD 45 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (ELVN)
| Next Earnings Date | 2026-05-13 |
|---|---|
| EPS Estimate | USD -0.37 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.38 vs est -0.41 ▲ beat |
| 2025-12-31 | USD -0.48 vs est -0.48 ▼ miss |
| 2025-09-30 | USD -0.32 vs est -0.47 ▲ beat |
| 2025-06-30 | USD -0.49 vs est -0.42 ▼ miss |
Source: Nexqual, June 10, 2026 at 01:10 UTC.
Financials & Fundamentals (ELVN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -26.64% |
| Debt / Equity | 0.07 |
| Current Ratio | 40.32 |
| Total Cash | $452.40M |
| Total Debt | $302,000 |
| Free Cash Flow | $-46.08M |
Source: Nexqual, June 10, 2026 at 01:10 UTC.
Financial Health Score (ELVN)
Nexqual rates Enliven Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 01:10 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $452M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$65M |
| Efficiency | Critical — ROE -27%, ROA -18.9% |
Ownership (ELVN)
| Insider Ownership | +7.52% |
|---|---|
| Institutional Ownership | +104.74% |
| Shares Outstanding | 60.90M |
| Float | 44.42M |
| Short % of Float | +13.55% |
Source: Nexqual, June 10, 2026 at 01:10 UTC.
Leadership (ELVN)
Enliven Therapeutics, Inc. is led by Richard A. Fair (age 56), CEO, President & Director, per Nexqual as of June 10, 2026 at 01:10 UTC.
| CEO, President & Director | Richard A. Fair (age 56) |
|---|---|
| CFO & Head of Corporate Development | Benjamin Hohl (age 36) |
| Co-Founder & COO | Anish Patel Pharm.D. (age 44) |
Major Backers & Investors (ELVN)
Notable institutional backers of Enliven Therapeutics, Inc. include Orbimed Advisors LLC., FMR, LLC, Polar Capital Holdings PLC, according to Nexqual as of June 10, 2026 at 01:10 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Orbimed Advisors LLC. | 13.07% |
| FMR, LLC | 11.21% |
| Polar Capital Holdings PLC | 8.32% |
| Fidelity | 7.8% |
| Commodore Capital Lp | 5.38% |
| Vestal Point Capital, LP | 5.34% |
| Bellevue Group AG | 3.81% |
| Fairmount Funds Management LLC | 3.05% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.57% |
| Vanguard Group | 7.03% |
Source: Nexqual, June 10, 2026 at 01:10 UTC.
From Enliven Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
- Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc. | USD 24.18 | ▲ 2.07% |
| EWTX | Edgewise Therapeutics, Inc. | USD 34.06 | ▼ 4.3% |
| SYRE | Spyre Therapeutics, Inc. | USD 76.44 | ▲ 3.79% |
| TYRA | Tyra Biosciences, Inc. | USD 25.94 | ▼ 2.63% |
| DNTH | Dianthus Therapeutics, Inc. | USD 84.57 | ▲ 5.04% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:10 UTC. This page is informational and not investment advice.